Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology and medical device company centered on precision fluid management for patients with cardio-renal conditions and fluid overload. News about Nuwellis frequently highlights clinical data, regulatory milestones, pediatric innovation, and business updates related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Readers of this NUWE news page can follow company announcements on topics such as new patents for extracorporeal safety technologies, NIH grant-supported development of the Vivian pediatric system, and multi-center registries like ULTRA-Peds that examine real-world Aquadex use in critically ill children. Nuwellis also issues news about clinical experiences at hospitals, including studies presented at nephrology conferences that explore Aquadex applications in acute kidney injury, post-cardiac-surgery fluid overload, and complex critical-care cases.
In addition to clinical and technology updates, Nuwellis regularly reports quarterly financial results, at-the-market equity offering arrangements, and other material events through press releases and SEC-referenced communications. These updates provide insight into revenue trends, product launches such as new catheter sizes or circuits, and strategic steps like focusing on U.S. market growth.
Investors, clinicians, and researchers can use this news feed to track how Nuwellis is advancing its Aquadex platform, expanding into pediatric and hospital-based outpatient settings, and progressing the Vivian pediatric CRRT system. Returning to this page allows users to monitor ongoing developments in the company’s cardio-renal strategy, intellectual property portfolio, and regulatory and clinical milestones associated with NUWE.
Nuwellis, Inc. announced the closing of a $2.7 million public offering, issuing 11,250,000 shares of common stock and warrants. The gross proceeds will be used for working capital and general corporate purposes, including investments in commercialization efforts.
Nuwellis, Inc. (NUWE) will report its first quarter 2024 financial results on May 7, 2024. The medical technology company will host a conference call and webcast to discuss the results and provide a business update.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.